Chronic Kidney Disease Proteinuria Hypertension Manidipine Proteinuria Chronic Kidney Disease Calcium Channel Blockers Antihypertensive Agents Renal Protection
Conditions
Interventions
Participants receive high-dose manidipine 40 mg once daily for the treatment of proteinuric chronic kidney disease. The study evaluates the antiproteinuric effect of high-dose manidipine compared with
Active Comparator Drug,Active Comparator Drug
High-dose Manidipine,Low-dose Manidipine
Sponsors
Navamindradhiraj University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Adult patients diagnosed with chronic kidney disease 2. Presence of proteinuria on laboratory testing 3. Receiving treatment with manidipine for blood pressure control 4. Available clinical data including urinary protein measurement and kidney function assessment
Exclusion criteria
Exclusion criteria: 1. Patients with acute kidney injury 2. Patients receiving dialysis or with end stage kidney disease 3. Patients with incomplete clinical data for urinary protein measurement 4. Patients receiving other medications that may significantly affect proteinuria 5. Patients with severe systemic illness or conditions affecting kidney function
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in urinary albumin excretion 6 months Urinary albumin to creatinine ratio measured from spot urine sample | — |
Secondary
| Measure | Time frame |
|---|---|
| Systolic blood pressure 6 months Blood pressure measured using standard sphygmomanometer | — |
Countries
Thailand
Contacts
Public ContactSathit Kurathong
Faculty of Medicine Vajira Hospital Navamindradhiraj University
Outcome results
None listed